Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8447610 | 0.91 | HINT1 (0.50) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL5352518 | 0.91 | HINT1 (0.50) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL22875468 | 0.91 | HINT1 (0.50) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL5355041 | 0.91 | HINT1 (0.50) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL5351509 | 0.89 | KDM4E (0.49) | POLBHINT1FUT5POLA1KDM4E | |
| SCHEMBL5351515 | 0.89 | KDM4E (0.49) | POLBHINT1FUT5POLA1KDM4E | |
| SCHEMBL22875444 | 0.86 | POLB (0.52) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL22875452 | 0.86 | POLB (0.52) | POLBHINT1F2FUT5P2RY2 | |
| SCHEMBL20434926 | 0.85 | POLB (0.55) | POLBHINT1FUT5P2RY2P2RY4 | |
| SCHEMBL9079838 | 0.84 | HINT1 (0.53) | POLBHINT1F2FUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | POLB 1121/4885HINT1 324/4885F2 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.